RxDoctor Payments Data

Dilfuza Makhmudova

Family · Dayton, OHNPI 1972269132

Payments from drug & device makers

$9,259in general payments, 2019–2025

Across 578 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$882
  • Novo Nordisk$738
  • GSK$735
  • Lilly USA, LLC$701
  • Corcept Therapeutics$578
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$9,259100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,259 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$42,711
Medicare patients
127
Services billed
935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide33$49,500
MounjaroTirzepatide27$35,723
EliquisApixaban24$31,839
OzempicSemaglutide27$30,142
JardianceEmpagliflozin17$26,318
JanuviaSitagliptin Phosphate13$21,602
Breo ElliptaFluticasone/Vilanterol32$15,039
Soliqua 100-33Insulin Glargine/Lixisenatide17$14,908
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$14,480
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$7,311
Combivent RespimatIpratropium/Albuterol Sulfate13$6,114
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,337
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,537
Albuterol Sulfate HfaAlbuterol Sulfate106$1,903
Levothyroxine Sodium178$1,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$701$85,22360 claims
Boehringer IngelheimJardiance, Combivent Respimat$396$32,43230 claims
PfizerEliquis$409$31,83924 claims
Novo NordiskOzempic$738$30,14227 claims
MerckJanuvia$75$21,60213 claims
GSKBreo Ellipta, Anoro Ellipta$735$20,37643 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$40$14,90817 claims
AstraZenecaBreztri Aerosphere$882$14,48021 claims
AbbVieSynthroid$2,281$1,47923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Dayton

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →